Stockreport

KalVista Pharmaceuticals (KALV) Is Up 22.4% After Early Success In Pivotal Pediatric HAE Trial [Yahoo! Finance]

KalVista Pharmaceuticals, Inc.  (KALV) 
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.kalvista.com
PDF rapid, well-tolerated on-demand treatment for 172 hereditary angioedema attacks in 33 children aged 2–11, a group that currently depends on injectable therapies. The t [Read more]